ArticleDiscover oncology2025
Machine learning-based prognostic modeling integrating PANoptosis in head and neck squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous and aggressive cancer, posing challenges for prognosis and treatment. The role of PANoptosis in HNSCC remains unclear, despite its potential impact on the tumor immune microenvironment.
methodsWe obtained the single-cell RNA sequencing dataset GSE181919 from the GEO database and used the AUCell R package to analyze PANoptosis enrichment and heterogeneity, identifying key PANoptosis-related genes at the single-cell level. A prognostic model was constructed using 101 machine learning algorithms and their combinations, with TCGA-HNSCC as the training set and GSE41613 and GSE65858 as validation sets. Model performance was assessed using Kaplan-Meier survival analysis, ROC curves, and PCA. Glutathione S-transferase omega 1 (GSTO1) was identified as a key model gene, and its expression was validated using PCR in clinical samples.
resultsWe integrated single-cell sequencing, bulk transcriptomic sequencing, and machine learning algorithms to construct a StepCox[backward] + RSF prognostic model for HNSCC. This model stratified HNSCC patients into high-risk and low-risk groups, with the high-risk group exhibiting worse prognosis. ROC and PCA analyses confirmed the model's robustness. Additionally, the key gene GSTO1 was identified and further validated to be upregulated in HNSCC and associated with poor prognosis.
conclusionsThe PANoptosis-based prognostic model offers strong predictive value for HNSCC and has potential applications in personalized treatment approaches. GSTO1 stands out as a promising biomarker and therapeutic target. Future research should focus on experimental validation and the development of therapeutic strategies that modulate PANoptosis to improve outcomes for HNSCC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.